Digital Therapeutics: Veridian’s 2026 Challenge

Dr. Aris Thorne, head of digital health initiatives at the fictional “Veridian Health System” in Seattle, stared at the Q3 2026 adoption rates for their flagship cardiovascular digital therapeutic (DTx). The numbers were stagnant, a flat line stubbornly refusing to climb past 15% of eligible patients. Veridian had invested heavily in this FDA-cleared application, designed to support patients with hypertension and chronic heart failure through personalized interventions and remote monitoring. The clinical results from initial trials were undeniable, showing significant improvements in patient adherence and health outcomes. Yet, despite the clear benefits, scaling these healthcare apps across their vast network proved to be a formidable challenge. The promise of digital therapeutics to transform chronic disease management was tantalizing, but its widespread integration into routine care remained elusive. How could Veridian, and the broader healthcare industry, truly unlock the potential of DTx by 2026?

Dr. Thorne’s team had carefully followed the playbook for launching a new medical device. They secured the necessary regulatory approvals from the U.S. Food and Drug Administration (FDA) for their DTx, “HeartPath,” a process that, by 2026, often involved the FDA’s Digital Health Center of Excellence guidance. They had even partnered with a leading academic institution for a strong post-market study, demonstrating HeartPath’s efficacy in a real-world setting. The problem wasn’t the product itself. It was the chasm between clinical validation and operational integration. “We have a life-changing tool,” Thorne mused during a particularly frustrating Monday morning meeting, “but it’s sitting on a shelf because our doctors aren’t prescribing it, and our patients aren’t consistently using it.”

The core issue, as Thorne’s analysis revealed, was multifaceted. First, there was the workflow integration problem. Physicians, already burdened with overflowing schedules and complex EHR systems, found it difficult to incorporate a new prescription pathway for a digital tool. HeartPath required a separate enrollment process, different from traditional medication orders, and its data didn’t flow directly into Veridian’s existing Epic EHR system. This meant manual data entry for nurses and physicians, a significant barrier in a system striving for efficiency. According to a 2025 report by the American Medical Association (AMA), administrative tasks, particularly EHR-related ones, remained a primary driver of physician burnout, making any additional burden a non-starter.

Second, provider education was insufficient. Many clinicians understood the concept of DTx but lacked hands-on experience or confidence in explaining HeartPath to patients. They were accustomed to prescribing pills, not apps. The training Veridian offered, while complete, was often seen as an “extra” rather than an essential part of their ongoing professional development. This led to a lack of physician championing, which is critical for any new treatment modality. When a doctor doesn’t enthusiastically recommend a tool, patient adoption inevitably suffers. I’ve observed this pattern repeatedly in technology rollouts across various industries: if the frontline users aren’t convinced, even the most innovative solution struggles for traction.

The third hurdle was patient engagement and retention. HeartPath offered personalized coaching and reminders, but many patients downloaded the app, used it a few times, and then forgot about it. There was no consistent follow-up mechanism from Veridian’s care teams to encourage continued use. The initial excitement wore off, replaced by the inertia of old habits. This isn’t unique to healthcare apps. Consumer apps face similar challenges. However, with DTx, the stakes are considerably higher, directly impacting health outcomes. The “set it and forget it” mentality, unfortunately, applies to many digital health solutions if not actively managed.

As Thorne mapped out these challenges, he realized Veridian needed a radical shift in strategy. The existing approach treated HeartPath as a standalone product. The future required it to be an integral part of the care continuum. His first priority became interoperability. “We need HeartPath to ‘talk’ to Epic,” he declared to his team. This meant investing in development resources to build strong APIs (Application Programming Interfaces) that adhered to HL7 FHIR (Fast Healthcare Interoperability Resources) standards, allowing patient data, prescription orders, and adherence metrics to flow smoothly between the DTx and the EHR. This would eliminate manual data entry, providing physicians a well-rounded view of patient progress without leaving their primary workflow.

Next, Thorne tackled provider education and incentives. He restructured the training program, making it mandatory for all cardiologists and primary care physicians referring patients with cardiovascular conditions. The new program included hands-on simulations, case studies demonstrating HeartPath’s impact, and peer-to-peer discussions. More importantly, he advocated for integrating DTx prescription and monitoring into existing performance metrics for physicians. If doctors were evaluated, in part, on their appropriate use of evidence-based digital tools, adoption would naturally follow. This required a cultural shift, certainly, but one that recognized DTx as a legitimate and valuable treatment option.

For patient engagement, Thorne looked beyond the initial download. He proposed a tiered support model. For high-risk patients, a dedicated care coordinator would routinely check in, offering technical assistance and motivational support. For others, the app itself would incorporate more sophisticated gamification elements and personalized feedback loops, dynamically adjusting to patient behavior. The goal was to build a “digital habit” rather than simply offering a tool. This meant using behavioral science principles, a field increasingly vital for effective digital therapeutics. The Digital Therapeutics Alliance (DTA), a global non-profit trade association, has consistently highlighted the importance of evidence-based behavioral interventions in DTx design.

A significant, often overlooked, aspect of scaling was reimbursement. By 2026, the field for DTx reimbursement was still evolving but showed promise. Thorne worked with Veridian’s billing department to identify and advocate for appropriate CPT (Current Procedural Terminology) codes for DTx prescription, onboarding, and ongoing monitoring. While direct DTx reimbursement codes were still emerging, some payers were beginning to cover DTx under broader remote patient monitoring or chronic care management codes. Securing clear reimbursement pathways was, in Thorne’s view, the ultimate accelerant for widespread adoption. Without financial viability, even the most effective DTx would struggle to find its place in the healthcare ecosystem. My personal opinion is that this is perhaps the biggest barrier remaining. If providers aren’t paid for it, they won’t use it. It’s that simple.

Six months later, the Q1 2027 report landed on Thorne’s desk. HeartPath’s adoption rate had climbed to 45% of eligible patients, with a 70% retention rate for those who started the program. The smooth integration with Epic had reduced physician burden by an estimated 30 minutes per patient per week, freeing up valuable time for direct patient care. Patient satisfaction scores related to HeartPath had also seen a significant jump, with many citing the personalized support and ease of use. Veridian Health System was becoming a model for how to effectively scale healthcare apps, moving beyond pilot programs to systemic integration. The journey was far from over, but the initial, daunting hurdles had been cleared. The lesson for other healthcare organizations was clear: scaling digital therapeutics is not just about developing innovative technology. It’s about fundamentally rethinking clinical workflows, helping providers, engaging patients, and securing sustainable financial models. It demands a well-rounded approach, recognizing that technology is merely a tool, and its true impact comes from its thoughtful integration into human-centered care.

The future of healthcare, undeniably, involves a greater reliance on digital tools. The success of digital therapeutics hinges on our ability to integrate these innovative solutions into the fabric of daily clinical practice, ensuring they become an intuitive extension of care rather than an additional burden. The experience at Veridian demonstrates that by focusing on interoperability, complete provider education, sustained patient engagement, and strong reimbursement, healthcare systems can effectively scale these powerful emerging tech solutions and genuinely improve patient outcomes.